🇺🇸 Ifosfamide + Mesna in United States

39 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Neutropenia — 7 reports (17.95%)
  2. Febrile Neutropenia — 6 reports (15.38%)
  3. Disease Progression — 5 reports (12.82%)
  4. Thrombocytopenia — 5 reports (12.82%)
  5. Anaemia — 4 reports (10.26%)
  6. Febrile Bone Marrow Aplasia — 4 reports (10.26%)
  7. Aspergillus Infection — 2 reports (5.13%)
  8. Atrial Fibrillation — 2 reports (5.13%)
  9. Cytopenia — 2 reports (5.13%)
  10. Dysphagia — 2 reports (5.13%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Ifosfamide + Mesna approved in United States?

Ifosfamide + Mesna does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ifosfamide + Mesna in United States?

Lymphoma Study Association is the originator. The local marketing authorisation holder may differ — check the official source linked above.